Selected article for: "active inhibitor and long range"
Author: Joseph, Raji E; Amatya, Neha; Fulton, D Bruce; Engen, John R; Wales, Thomas E; Andreotti, Amy
Title: Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
  • Cord-id: 8desqtsw
  • Document date: 2020_11_23
    • ID: 8desqtsw
    Snippet: Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site. While effective at blocking the catalytic activity of BTK, consequences of drug binding on the global conformation of full-length BTK are unknown. Here, we uncover a range of conformational effects in full-length BTK induced by a panel of act
    Document: Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site. While effective at blocking the catalytic activity of BTK, consequences of drug binding on the global conformation of full-length BTK are unknown. Here, we uncover a range of conformational effects in full-length BTK induced by a panel of active site inhibitors, including large-scale shifts in the conformational equilibria of the regulatory domains. Additionally, we find that a remote Ibrutinib resistance mutation, T316A in the BTK SH2 domain, drives spurious BTK activity by destabilizing the compact autoinhibitory conformation of full-length BTK, shifting the conformational ensemble away from the autoinhibited form. Future development of BTK inhibitors will need to consider long-range allosteric consequences of inhibitor binding, including the emerging application of these BTK inhibitors in treating COVID-19.

    Search related documents:
    Co phrase search for related documents
    • absence presence and active conformation: 1, 2, 3
    • absence presence and active inactive: 1
    • absence presence and active inactive conformation: 1
    • absence presence and active site: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and active site binding: 1, 2, 3, 4
    • absence presence and active site pocket: 1
    • absence presence and activity assay: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and activity block: 1
    • absence presence and activity control: 1, 2, 3
    • absence presence and activity increase: 1, 2, 3
    • absence presence and local structure: 1
    • absence presence and long range: 1
    • absence presence and low energy: 1
    • absence presence and lymphoma leukemia: 1
    • absence presence and lysis buffer: 1, 2, 3, 4, 5
    • absence presence and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13